Q1 2025 United Therapeutics Corp Earnings Call Transcript

Apr 30, 2025 / 01:00PM GMT

Release Date Price: R$102.5

Transcript 8-K10-Q

Key Points

Positve

United Therapeutics Corp (UTHR) reported a record revenue quarter, marking the ninth time in the past twelve quarters.
Revenue growth was driven by strong performance across all treprostinil products, including Tyvaso, Orenitram, Remodulin, and Unituxin.
The company is experiencing consistent patient demand and strong referrals for its products, indicating robust market presence.
UTHR has five registration phase studies underway and a pending FDA marketing application, showcasing a strong pipeline.
The company maintains strict financial discipline, spending no more than 50% of prior year revenue on cash operating expenses, resulting in over $1 billion in annual operating cash flow.

Negative

The UThymoKidney program faced a setback with a patient requiring explantation due to an unrelated infection, highlighting challenges in clinical trials.
Despite strong revenue growth, the competitive landscape in the PAH space is intensifying, which could impact future market share.
The company faces obligations under the Part D redesign, which could affect financial performance.
There is uncertainty regarding the impact of new competitors, such as Insmed's TPIP, on UTHR's market position.
The company did not provide specific revenue guidance, leaving some uncertainty about future financial performance.

Operator

Good morning and welcome to the United Therapeutics Corporation first quarter 2025 corporate update. My name is Tobin and I will be your conference operator today. (Operator Instructions) Please note, this call is being recorded.

I would now like to turn the webcast over to Dewey Steadman, Head of Investor Relations at United Therapeutics. Please go ahead.

Dewey Steadman

United Therapeutics Corp - Head of Investor & Media Relations

Thank you, Tobin, and good morning. It is my pleasure to welcome you to the United Therapeutics Corporation first quarter 2025 corporate update webcast. Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events.

These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q, contain additional information on these risks and uncertainties, and we assume no obligation to update these forward-looking statements.

Today's remarks may discuss the progress

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.